Subscribe
The Aducanumab Aftermath: The Industry

Tradeoffs

The Aducanumab Aftermath: The Industry

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag? This is the last…
June 25, 2021

The Aducanumab Aftermath: The Industry

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?

This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.

Guest:

Luke Timmerman, Journalist/Founder, Timmerman Report

Explore the full series and additional resources: https://tradeoffs.org/aducanumab

Read a transcript of this episode: 

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter

Support this type of journalism today, with a gift: https://tradeoffs.org/donate

Follow us on Twitter: https://twitter.com/tradeoffspod

 


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Proudly supported by:

cover
Nurses You Should Know with Joanna Uribe MSN, RN and Sandy Cayo DNP, FNP-BC, RN Listen to this very important and timely discussion on Nurses You Should Know!